 | Up a level |
2019
Schneeweiss, Andreas, Moebus, Volker, Tesch, Hans, Hanusch, Claus, Denkert, Carsten, Luebbe, Kristina, Huober, Jens, Klare, Peter, Kuemmel, Sherko, Untch, Michael, Kast, Karin, Jackisch, Christian, Thomalla, Joerg, Ingold-Heppner, Barbara, Blohmer, Jens-Uwe, Rezai, Mahdi, Frank, Matthias, Engels, Knut, Rhiem, Kerstin, Fasching, Peter Andreas, Nekljudova, Valentina, von Minckwitz, Gunter and Loibl, Sibylle (2019). Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial. Eur. J. Cancer, 106. S. 181 - 193. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852
2014
Locatelli, Giuseppe 
ORCID: 0000-0002-2179-4407, Krueger, Martin, da Costa, Olivia Prazeres, Ingold-Heppner, Barbara, Koch, Linda, Schreiner, Bettina, Bruening, Jens, Bechmann, Ingo, Becher, Burkhard ORCID: 0000-0002-1541-7867 and Buch, Thorsten ORCID: 0000-0002-2236-9074
(2014).
Loss of IGF1R from oligodendrocytes ameliorates neuroinflammation without affecting cell survival.
J. Neuroimmunol., 275 (1-2).
S. 123 - 124.
AMSTERDAM:
ELSEVIER SCIENCE BV.
ISSN 1872-8421